ALPHARETTA, Ga.–(BUSINESS WIRE)–Clearside Biomedical, a clinical-stage biopharmaceutical company developing innovative first-in-class drug therapies for diseases of the eye, announces completion of $20 million Series C financing.
Uncategorized
rhNGF, het biotech molecuul van Dompé voor de behandeling van neurotrofe keratitis, ontvangt weesgeneesmiddelaanduiding van het Europees Geneesmiddelenbureau
MILAAN–(BUSINESS WIRE)–Het biofarmaceutisch bedrijf Dompé heeft vandaag aangekondigd dat het Comité voor weesgeneesmiddelen van het Europees Geneesmiddelenbureau (EMA) de recombinante humane zenuwgroeifactor (rhNGF) – het experimentele biotech molecuul ontwikkeld door Dompé op basis van onderzoek door Nobelprijswinnaar Rita Levi Montalcini – officieel heeft aangeduid als een weesgeneesmiddel voor de behandeling van neurotrofe keratitis. NGF is de eerste neurotrofe factor die geïdentificeerd e
Readers Name Biggest Medical Stories of 2015
The debut of the ICD-10 diagnostic codes topped the list, followed by California’s approval of physician-assisted suicide. The end of the 10-year MOC exam ranked as the most exciting piece of news. Medscape Medical News
rhNGF, la molecola biotecnologica Dompé per la cura della cheratite neurotrofica, designato farmaco orfano dalla European Medicines Agency
MILANO–(BUSINESS WIRE)–L’azienda biofarmaceutica Dompé annuncia che il Comitato per i Farmaci Orfani dell’EMA (European Medicines Agency) ha ufficialmente designato rhNGF, la molecola biotecnologica sperimentale messa a punto dalla ricerca Dompé sulla scorta degli studi del Premio Nobel per la Medicina Rita Levi Montalcini, come farmaco orfano per il trattamento della cheratite neurotrofica. NGF (Nerve Growth Factor) è il primo fattore neurotrofico a essere identificato e purificato e, oggi,
rhNGF, the Dompé Biotech Molecule for the Treatment of Neurotrophic Keratitis, Receives Orphan Drug Designation from the European Medicines Agency
MILAN–(BUSINESS WIRE)–The Dompé biopharmaceutical company announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has officially designated recombinant human Nerve Growth Factor (rhNGF) – the investigational biotech molecule developed by Dompé based on research by Nobel Laureate Rita Levi Montalcini – as an orphan drug for the treatment of neurotrophic keratitis. NGF is the first neurotrophic factor to be identified and purified, and represents
Uncategorized
Trabeculectomy has little impact on IOL power calculations
Trabeculectomy had a minimal effect on IOL power calculation despite significant changes in axial length and corneal power, according to a study.The prospective study included 34 eyes of 31 patients with a mean age of 53.35 years who were scheduled to …